Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03556904 · ClinicalTrials.gov registry record · Phase 2
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
A Phase 2 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
NCT03556904 is a Phase 2 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 14 participants.
The verdict
NCT03556904, a Phase 2 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
Study Summary
This clinical trial will determine whether the addition of radiotherapy to standard of care systemic therapy improves objective progression-free survival compared to systemic therapy alone in patients with oligometastatic castration-resistant prostate cancer.
Interventions
- RADIATION Ablative Radiation Therapy
- DRUG Hormone therapy or chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2018-12-10 |
| Est. Completion | 2023-07-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03556904
The ClinicalTrials.gov registry entry for NCT03556904 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ablative Radiation Therapy is the first listed.
NCT03556904 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03556904 about?
NCT03556904 is a clinical study titled "FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)". This clinical trial will determine whether the addition of radiotherapy to standard of care systemic therapy improves objective progression-free survival compared to systemic therapy alone in patients with oligometastatic castration-resistant prostate cancer.
What is the current status of trial NCT03556904?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2018-12-10. Estimated completion is 2023-07-28.
What interventions are being tested in trial NCT03556904?
The interventions under investigation include: Ablative Radiation Therapy (RADIATION), Hormone therapy or chemotherapy (DRUG).
Who is sponsoring clinical trial NCT03556904?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.